| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
|
Ramanathan, Ramesh K.
|
|
2009
|
64 |
4 |
p. 777-783
|
article
|
| 2 |
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer
|
Bozionelou, Vasiliki
|
|
2009
|
64 |
4 |
p. 785-791
|
article
|
| 3 |
A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen
|
Ruff, Paul
|
|
2009
|
64 |
4 |
p. 763-768
|
article
|
| 4 |
Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents
|
Morgan, Lee Roy
|
|
2009
|
64 |
4 |
p. 829-835
|
article
|
| 5 |
Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine
|
Noble, Charles O.
|
|
2009
|
64 |
4 |
p. 741-751
|
article
|
| 6 |
Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts
|
Sardão, Vilma A.
|
|
2009
|
64 |
4 |
p. 811-827
|
article
|
| 7 |
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
|
Brandes, Alba A.
|
|
2009
|
64 |
4 |
p. 769-775
|
article
|
| 8 |
Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of γ-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells
|
Asano, Takeshi
|
|
2009
|
64 |
4 |
p. 715-721
|
article
|
| 9 |
Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation
|
Cornejo, Agustin
|
|
2009
|
64 |
4 |
p. 857-860
|
article
|
| 10 |
Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice
|
Nakashima-Kamimura, Naomi
|
|
2009
|
64 |
4 |
p. 753-761
|
article
|
| 11 |
MTT assays can underestimate cell numbers
|
Liu, Wai M.
|
|
2009
|
64 |
4 |
p. 861-862
|
article
|
| 12 |
Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity
|
Liu, Johnson J.
|
|
2009
|
64 |
4 |
p. 847-856
|
article
|
| 13 |
Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer
|
Nolè, Franco
|
|
2009
|
64 |
4 |
p. 673-680
|
article
|
| 14 |
Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer
|
Lee, Gyeong-Won
|
|
2009
|
64 |
4 |
p. 707-713
|
article
|
| 15 |
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
|
Pavlick, Anna C.
|
|
2009
|
64 |
4 |
p. 803-810
|
article
|
| 16 |
Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma
|
Hingorani, Pooja
|
|
2009
|
64 |
4 |
p. 733-740
|
article
|
| 17 |
Pro-apoptotic and cytostatic activity of naturally occurring cardenolides
|
Bloise, Elena
|
|
2009
|
64 |
4 |
p. 793-802
|
article
|
| 18 |
Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane
|
Attia, Sabry M.
|
|
2009
|
64 |
4 |
p. 837-845
|
article
|
| 19 |
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
|
Lee, Jeeyun
|
|
2009
|
64 |
4 |
p. 657-663
|
article
|
| 20 |
Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species
|
Haznedar, Joshua Ö.
|
|
2009
|
64 |
4 |
p. 691-706
|
article
|
| 21 |
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
|
Conroy, Andrew
|
|
2009
|
64 |
4 |
p. 723-732
|
article
|
| 22 |
Temozolomide in malignant gliomas: current use and future targets
|
Villano, J. Lee
|
|
2009
|
64 |
4 |
p. 647-655
|
article
|
| 23 |
The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties
|
Beyer, Carl F.
|
|
2009
|
64 |
4 |
p. 681-689
|
article
|
| 24 |
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study
|
Saunders, Mark P.
|
|
2009
|
64 |
4 |
p. 665-672
|
article
|
Journal description